Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?
The unexpectedly low vaccine efficacy of Dengvaxia®, developed by Sanofi Pasteur, and a higher risk of severe diseases after vaccination among dengue-naive children or children younger than 6 years old, have cast skepticism about the safety of dengue vaccination resulting in the suspension of school...
| Main Authors: | , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2019-10-01
|
| Series: | Human Vaccines & Immunotherapeutics |
| Subjects: | |
| Online Access: | http://dx.doi.org/10.1080/21645515.2019.1643676 |
| _version_ | 1797677377143177216 |
|---|---|
| author | Jedhan Ucat Galula Gielenny M. Salem Gwong-Jen J. Chang Day-Yu Chao |
| author_facet | Jedhan Ucat Galula Gielenny M. Salem Gwong-Jen J. Chang Day-Yu Chao |
| author_sort | Jedhan Ucat Galula |
| collection | DOAJ |
| description | The unexpectedly low vaccine efficacy of Dengvaxia®, developed by Sanofi Pasteur, and a higher risk of severe diseases after vaccination among dengue-naive children or children younger than 6 years old, have cast skepticism about the safety of dengue vaccination resulting in the suspension of school-based immunization programs in the Philippines. The absence of immune correlates of protection from dengue virus (DENV) infection hampers the development of other potential DENV vaccines. While tetravalent live-attenuated tetravalent vaccines (LATVs), which mimic natural infection by inducing both cellular and humoral immune responses, are still currently favored, developing a vaccine that provides a balanced immunity to all four DENV serotypes remains a challenge. With the recently advanced understanding of virion structure and B cell immune responses from naturally infected DENV patients, two points of view in developing a next-generation dengue vaccine emerged: one is to induce potent, type-specific neutralizing antibodies (NtAbs) recognizing quaternary structure-dependent epitopes by having four components of vaccine strains replicate equivalently; the other is to induce protective and broadly NtAbs against the four serotypes of DENV with a universal vaccine. This article reviews the studies related to these issues and the current knowledge gap that needs to be filled in. |
| first_indexed | 2024-03-11T22:44:12Z |
| format | Article |
| id | doaj.art-e07d5da1d47e4fb193fa08a2067a874f |
| institution | Directory Open Access Journal |
| issn | 2164-5515 2164-554X |
| language | English |
| last_indexed | 2024-03-11T22:44:12Z |
| publishDate | 2019-10-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Human Vaccines & Immunotherapeutics |
| spelling | doaj.art-e07d5da1d47e4fb193fa08a2067a874f2023-09-22T08:45:32ZengTaylor & Francis GroupHuman Vaccines & Immunotherapeutics2164-55152164-554X2019-10-0115102328233610.1080/21645515.2019.16436761643676Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era?Jedhan Ucat Galula0Gielenny M. Salem1Gwong-Jen J. Chang2Day-Yu Chao3National Chung Hsing UniversityNational Chung Hsing UniversityUS Department of Health and Human ServicesNational Chung Hsing UniversityThe unexpectedly low vaccine efficacy of Dengvaxia®, developed by Sanofi Pasteur, and a higher risk of severe diseases after vaccination among dengue-naive children or children younger than 6 years old, have cast skepticism about the safety of dengue vaccination resulting in the suspension of school-based immunization programs in the Philippines. The absence of immune correlates of protection from dengue virus (DENV) infection hampers the development of other potential DENV vaccines. While tetravalent live-attenuated tetravalent vaccines (LATVs), which mimic natural infection by inducing both cellular and humoral immune responses, are still currently favored, developing a vaccine that provides a balanced immunity to all four DENV serotypes remains a challenge. With the recently advanced understanding of virion structure and B cell immune responses from naturally infected DENV patients, two points of view in developing a next-generation dengue vaccine emerged: one is to induce potent, type-specific neutralizing antibodies (NtAbs) recognizing quaternary structure-dependent epitopes by having four components of vaccine strains replicate equivalently; the other is to induce protective and broadly NtAbs against the four serotypes of DENV with a universal vaccine. This article reviews the studies related to these issues and the current knowledge gap that needs to be filled in.http://dx.doi.org/10.1080/21645515.2019.1643676dengue virusdenguevirus-like particlesmaturitybroadly neutralizing antibody |
| spellingShingle | Jedhan Ucat Galula Gielenny M. Salem Gwong-Jen J. Chang Day-Yu Chao Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era? Human Vaccines & Immunotherapeutics dengue virus dengue virus-like particles maturity broadly neutralizing antibody |
| title | Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era? |
| title_full | Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era? |
| title_fullStr | Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era? |
| title_full_unstemmed | Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era? |
| title_short | Does structurally-mature dengue virion matter in vaccine preparation in post-Dengvaxia era? |
| title_sort | does structurally mature dengue virion matter in vaccine preparation in post dengvaxia era |
| topic | dengue virus dengue virus-like particles maturity broadly neutralizing antibody |
| url | http://dx.doi.org/10.1080/21645515.2019.1643676 |
| work_keys_str_mv | AT jedhanucatgalula doesstructurallymaturedenguevirionmatterinvaccinepreparationinpostdengvaxiaera AT gielennymsalem doesstructurallymaturedenguevirionmatterinvaccinepreparationinpostdengvaxiaera AT gwongjenjchang doesstructurallymaturedenguevirionmatterinvaccinepreparationinpostdengvaxiaera AT dayyuchao doesstructurallymaturedenguevirionmatterinvaccinepreparationinpostdengvaxiaera |